ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: PUB135

Experience with Directly Acting Antiviral Agents for Hepatitis C in Maintenance Hemodialysis Patients in a Single Center from Pakistan

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Rashid, Raja Muhammad, CPSP, Islamabad, Pakistan
  • Nabi, Zahid, KRL Hospital, Islamabad, Pakistan
  • Zahideen, Zahid ul, Department of Nephrology KRL islamabad, Sialkot, Pakistan
Background

The prevalence of Hepatitis C in Pakistan is around 6 % in general population. Prevalence of hepatitis C in manintenance HD paients is between 22 to 55%. Seroconversion rates are reportedly one of the highest in the world.

Methods

Patients on maintenance HD at our center were included in the study. All the patients recieved sofosbuvir with one of the other available oral antiviral agents. Pertinent data at baseline , 3 months, 6 months and 12 months.

Results

Total of 31 patients were included in the study with Mean age of 50.3 years with Standard Deviation of 16.8. Twenty patients were male (64.5%) and Eleven were Female (35.5%). Duration of Hemodialysis prior to starting treatment was 2 months to 150 months. Four different regimens were used depending upon the availability of Drugs all of them containing Sofosbuvir in dose of 400mg OD. Pre-treatment PCR was Positive in all patients. SVR at end of therapy that is 3 months was achieved in all patients that completed study period. One patient had relapsed after 15months of achieving SVR (previously treated with Sofosbuvir and ribazole). Successfully treated with sofosbuvir plus valpatasvir for 4 months and achieved SVR successfully. Only 4 patients experienced Anemia, all recieving ribazole.

Conclusion

DAA based therapy delivered expected and desired results of therapy without any major therapy related adverse events in our center.